Moving healthcare forward

Achaogen (AKAO) is a biopharmaceutical company developing small molecule therapeutics to treat infections caused by multi-drug resistant bacteria. IPO in March 2014.

Akouos (AKUS) is a biotechnology company developing novel gene therapies for the treatment of monogenic forms of congenital deafness.

Alexza (ALXA) is a biopharmaceutical company developing drugs for local and systemic delivery through the lung.

Ambrx is a biopharmaceutical company which integrates recombinant protein synthesis with medicinal chemistry to develop protein drugs for a range of therapeutic areas.

Aprea (APRE) is a biopharmaceutical company developing small molecule therapeutics for the treatment of cancer by reactivating mutant p53 tumor suppressor function.

Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies to treat cancer.

Arvinas (ARVN) is a biopharmaceutical company developing small molecule therapeutics that target protein degradation with applications in cancer and other diseases.

Audentes, now Astellas Gene Therapies, a biotechnology company developing viral-based gene therapy for serious, rare diseases including genetic musculoskeletal disorders. Acquired by Astellas in December 2019.

Bellerophon (BLPH) is a clinical-stage biopharmaceutical company developing novel drugs and devices for the treatment of cardiopulmonary and cardiac diseases.

Bird Rock Bio was a clinical-stage biopharmaceutical company developing biologic therapies for the treatment of rheumatory arthritis and liver disease. Acquired by Skye Biosciences in 2023.

Cabaletta Bio (CABA) is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases

Calibrium is a biopharmaceutical company developing next generation insulins to treat diabetes and obesity. Acquired by Novo Nordisk (NVO) in August 2015.

Camp4 is a preclinical biotech company with core thesis to restore healthy gene expression in diseased cells by programmable modulation of a new class of RNA.

Cellular Research is a life science instrument company developing high resolution systems for the investigation of single cells and limited samples. Acquired by Becton Dickinson (BDX) in August 2015.

Ceterix is a medical device company developing products to improve outcome for minimally invasive arthroscopic surgeries.

Chrono was a biopharmaceutical company developing wearable and programmable therapeutics leveraging novel drug delivery technologies.

Cidara (CDTX) is a clinical-stage biopharmaceutical company developing therapeutics for serious fungal infections.

CinCor (CINC) is a clinical-stage biopharmaceutical company with a mission to advance clinical candidates in the area of cardiovascular disease. Acquired by AstraZeneca in 2023.

Crinetics (CRNX) is a biopharmaceutical company developing oral small molecule therapeutics for endocrine diseases.

Dianthus Therapeutics (DNTH) is a biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies for the treatment of severe and rare autoimmune diseases. Merged into public company in September 2023

DVS is a life science instrument company commercializing a mass cytometry for characterizing individual cells based on cell surface proteins. Acquired by Fluidigm (FLDM) in February 2014.

Enliven Therapeutics (ELVN) is a precision oncology company developing best in class and first in class small molecule therapies to extend and improve patient lives. Merged into a public company in February 2023.

Ensoma is a biotechnology company pioneering a next-generation in vivo approach to genetically engineer bone marrow stem cells that will broaden access to curative genetic medicines

Entrada (TRDA) is a biotechnology company focused on transforming the treatment of devastating diseases through the intracellular delivery of biologics.

Envoy is a drug discovery company with a cell-specific gene expression profiling platform, enabling novel target discovery, such as for the central nervous system. Acquired by Takeda (TKPHF) in November 2012.

Epirus (EPRS) is a global biopharmaceutical company focused on pure-play biosimilar business to improve patient access to cost-effective medicines. Merged into public company in July 2014.

Escient Pharmaceuticals develops and manufactures molecules that target a novel class of receptors for the treatment of neuro-immuno-inflammatory and autoreactive diseases.

Expansion Therapeutics is a drug discovery and development company focused on RNA-targeted small molecule therapeutics for the treatment of expansion repeat disorders.

Flexion (FLXN) is a clinical-stage biopharmaceutical company developing intra-articular sustained release therapeutics for the treatment of musculoskeletal diseases.

GlycoEra is a biotechnology company developing a glycoengineering platform to build novel therapeutics that will treat diseases in autoimmune, immuno-oncology, and inflammatory indications.

Halio, Inc. is a materials research company developing "adaptive" window technology for residential, automotive and commercial application.

Homology Medicines, Inc. (FIXX) translates proprietary, next generation gene editing and gene therapy technology into novel treatments for patients with rare diseases.

Ideaya Biosciences uses small molecules as novel personalized cancer therapies, leveraging direct targeting of oncogenic pathways and synthetic lethality – an emerging class of precision medicine targets.

Igenica is a biopharmaceutical company developing antibodies and antibody-drug conjugates for the treatment of cancer.

Ikaria is a commercial-stage biopharmaceutical company developing therapeutic gases for critical care applications. Acquired by Madison Dearborn Partners in February 2014.

Ilypsa is a biopharmaceutical company developing non-absorbed therapeutics for renal and metabolic diseases. Acquired by Amgen (AMGN) in July 2007.

Impel Neuropharma (IMPL) is a drug delivery company developing intranasal treatments for central nervous system disorders

Incline is a biopharmaceutical company developing a transdermal iontophoretic patch for patient controlled analgesia following surgery. Acquired by The Medicines Company (MDCO) in January 2013.

Inipharm is a biopharmaceutical company focused on developing small molecules that impact genetically-validated human targets to treat serious diseases of the liver.

KaloBios (KBIO) is a biopharmaceutical company developing human antibody therapeutics for oncology and respiratory diseases. IPO'ed in 2013 and is now known as Humanigen, Inc (HGEN).

Kinaset Therapeutics is a biopharmaceutical company developing inhaled small molecules for respiratory diseases

Latigo is a clinical-stage biotechnology company developing non-opioid pain medicines that target pain at its source

Magnetic Insight is a life science tools company developing Magnetic Particle Imaging to accelerate preclinical research with direct translation into the clinic

Marcadia is a biopharmaceutical company focused on developing therapeutics for the treatment of diabetes and obesity. Acquired by Roche (RHHBY) in December 2010.

Miikana is a clinical-stage biopharmaceutical company developing small molecule therapeutics for cancer. Acquired by EntreMed, a 5AM company, in January 2006.

Millendo is a biopharmaceutical company developing small molecule therapeutics for polycystic ovarian syndrome, adrenocortical carcinoma and congenital adrenal hyperplasia.

Neurogastrx is a biopharmaceutical company developing therapies for the treatment of functional and motility gastrointestinal disorders.

Nido Bio is developing oral small molecules for genetically validated neurodegeneration targets

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation

Nouscom is a biotechnology company developing genetic vaccines with the ability to target tumor neoantigens delivered through viral vectors.

Novira is a biopharmaceutical company developing small molecule therapeutics targeting viral capsid to treat Chronic Hepatitis B. Acquired by Johnson & Johnson (JNJ) in December 2015.

Nvelop is a preclinical company engineering programmable, non-viral vehicles for targeted in vivo delivery of therapeutic and editing cargoes to a wide range of tissues for the treatment of previously undruggable diseases.

Panomics is a research instrument and reagents company which develops cell-based assays and instruments for quantitative multiplexed measurements of molecular events. Acquired by Affymetrix (AFFX) in December 2008.

Pear (PEAR) is a biopharmaceutical company combining existing medications with digital software to improve patient outcomes. Merged into public company in December 2021.

Pearl is a biopharmaceutical company developing inhalable formulations for the treatment of respiratory diseases such as chronic obstructive pulmonary disease. Acquired by AstraZeneca (AZN) in June 2013.

PhaseRx (PZRX) is a biotechnology company developing polymer-based technology to delivery mRNA nanoparticles for the treatment of orphan diseases.

Portal is a biopharmaceutical company developing needle-free drug delivery system for the injection of large molecules.

Precede Bio is a first in class liquid biopsy platform focused on enabling access to therapeutically actionable disease-defining transcriptional biology.

PNI is a life science instrument and reagent company developing systems for the discovery and development of novel nanoparticles for biomedical use. Acquired by Danaher Corporation in June 2021

Pulmatrix (PULM) is a pharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Merged into public company in June 2015.

Purigen is a life sciences instruments and reagents company developing novel systems for integrated sample extraction and preparation for genomics applications. Purigen was acquired by Bionano Genomics in December 2022

Radionetics is a precision oncology company focused on radiopharmaceutical drug candidates for the treatment of a broad range of oncology indications.

Rallybio (RLYB) is a clinical-stage biotechnology company focused on identifying and accelerating the development of transformative breakthrough therapies for patients with severe and rare disorders.

RareCyte offers Precision Biology solutions focused on multiplexed tissue and single cell analysis of cells and tissue with applications in both research and clinical diagnostics.

Relypsa (RLYP) is a commercial-stage biopharmaceutical company developing non-absorbed polymeric drugs, including a potassium-binding agent for hyperkalemia associated with cardiovascular and renal diseases.

Rennovia was a materials research company developing chemocatalytic processes for converting biorenewable feedstocks into high value and commodity chemicals.

Scientist.com is a marketplace solution for accelerating the pace of pharmaceutical research and development.

scPharmaceuticals (SCPH) is a biopharmaceutical company developing therapeutics with enhanced drug delivery using a convenient, self-administering subcutaneous micropump technology.

Semprus is a medical device company developing permanent antimicrobial and anti-biofouling surfaces for use on indwelling devices. Acquired by Teleflex (TFX) in May 2012.

Skye (SKYE) is a clinical-stage company focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor, to treat diseases with inflammatory, fibrotic, and metabolic processes.

Synosia is a biopharmaceutical company developing and commercializing products for neurodegenerative and psychiatric disorders. Acquired by Biotie, a 5AM company, in February 2011.

TMRW is the world’s first and only integrated platform for automated, software-guided cryospecimen management. With ivfOS™, TMRW provides 100% chain of custody to safeguard the precious eggs and embryos used in IVF.

VBI Vaccines is a biopharmaceutical company developing vaccines against Cytomegalovirus and other pathogens. Merged into public company in July 2014.

Viveve (VIVE) is a medical device company commercializing a non-surgical, non-ablative medical device for use in women's health. Merged into public company in September 2014.

Vor Biopharma (VOR) is a biotechnology company engineering hematopoietic stem cells for transplant in the treatment of hematological malignancies.

Wildcat is a materials research company developing advanced battery materials for consumer and industrial applications.